INS and Hypoglycemia: Clinical studies conducted prior to 2010 had established the comparable glucose-lowering efficacy, yet the significantly lower risk of hypoglycemia with Gla-100 compared to neutral protamine Hagedorn (NPH) insulin (Table 1) [6-18].